Trial · NCT03045406

Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer

NCT03045406, Phase 3, Completed, Fadoi Foundation, Italy; results first posted 2025-06-18

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer. Trials, record NCT03045406. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03045406

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer
NCT number: NCT03045406
Status: Completed
Phases: Phase 3
Enrollment: 1,170 participants, actual
Lead sponsor: Fadoi Foundation, Italy
Conditions: Venous Thromboembolism
Interventions: Apixaban, Dalteparin
First posted: 2017-02-07
Last updated: 2025-06-24
Results first posted: 2025-06-18

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Recurrent Venous Thromboembolism	6 months	Primary efficacy outcome: objectively confirmed recurrent VTE occurring during the study period, that means the composite of: · proximal DVT of the lower limbs (symptomatic or unsuspected), DVT of the upper limb (symptomatic), PE (symptomatic or unsuspected)

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Recurrent Venous Thromboembolism	6 months		Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group2

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Recurrent Venous Thromboembolism	Apixaban		32		Participants
Recurrent Venous Thromboembolism	Dalteparin		46		Participants

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Apixaban	585
Overall Study	STARTED	Dalteparin	585
Overall Study	COMPLETED	Apixaban	399
Overall Study	COMPLETED	Dalteparin	382
Overall Study	NOT COMPLETED	Apixaban	186
Overall Study	NOT COMPLETED	Dalteparin	203

Source ClinicalTrials.gov

Adverse events586

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Anaemia	Blood and lymphatic system disorders	Apixaban	33	576	38
other	Anaemia	Blood and lymphatic system disorders	Dalteparin	21	579	27
other	Epistaxis	Respiratory, thoracic and mediastinal disorders	Apixaban	33	576	38
other	Epistaxis	Respiratory, thoracic and mediastinal disorders	Dalteparin	24	579	28
other	Dyspnoea	Respiratory, thoracic and mediastinal disorders	Apixaban	23	576	23
other	Dyspnoea	Respiratory, thoracic and mediastinal disorders	Dalteparin	29	579	36
serious	Anaemia	Blood and lymphatic system disorders	Apixaban	6	576	6
serious	Anaemia	Blood and lymphatic system disorders	Dalteparin	4	579	5
serious	Thrombocytopenia	Blood and lymphatic system disorders	Apixaban	5	576	6
serious	Thrombocytopenia	Blood and lymphatic system disorders	Dalteparin	4	579	4

1 to 10 of 586Source ClinicalTrials.gov

See all 586 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Apixaban	135	576
Total, all-cause mortality	Dalteparin	153	579
Total, other adverse events	Apixaban	89	576
Total, other adverse events	Dalteparin	74	579
Total, serious adverse events	Apixaban	255	576
Total, serious adverse events	Dalteparin	276	579

Source ClinicalTrials.gov

Papers3

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
32223112	DERIVED	PubMed
34260816	DERIVED	PubMed
34382385	DERIVED	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons3

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Apixaban vs Dalteparin: Recurrent Venous Thromboembolism	Trial comparisons
Apixaban vs Dalteparin: deaths from any cause	Trial comparisons
Apixaban vs Dalteparin: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT03045406

GET https://conductscience.org/api/trials/v1/NCT03045406/events?page=2

API reference For AI assistants